HK1217695A1 - 布魯頓氏酪氨酸激酶抑制劑 - Google Patents

布魯頓氏酪氨酸激酶抑制劑

Info

Publication number
HK1217695A1
HK1217695A1 HK16105564.7A HK16105564A HK1217695A1 HK 1217695 A1 HK1217695 A1 HK 1217695A1 HK 16105564 A HK16105564 A HK 16105564A HK 1217695 A1 HK1217695 A1 HK 1217695A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
tyrosine kinase
brutons tyrosine
brutons
kinase
Prior art date
Application number
HK16105564.7A
Other languages
English (en)
Inventor
Vicente Fidalgo Javier De
Romyr Dominique
Francisco Javier Lopez-Tapia
Sung-Sau So
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1217695A1 publication Critical patent/HK1217695A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16105564.7A 2013-03-05 2016-05-16 布魯頓氏酪氨酸激酶抑制劑 HK1217695A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772938P 2013-03-05 2013-03-05
PCT/EP2014/054017 WO2014135473A1 (en) 2013-03-05 2014-03-03 Inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
HK1217695A1 true HK1217695A1 (zh) 2017-01-20

Family

ID=50272581

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105564.7A HK1217695A1 (zh) 2013-03-05 2016-05-16 布魯頓氏酪氨酸激酶抑制劑

Country Status (11)

Country Link
US (1) US9469644B2 (zh)
EP (1) EP2964647A1 (zh)
JP (1) JP2016513621A (zh)
KR (1) KR20150113195A (zh)
CN (1) CN105073750A (zh)
BR (1) BR112015021677A2 (zh)
CA (1) CA2902375A1 (zh)
HK (1) HK1217695A1 (zh)
MX (1) MX2015010466A (zh)
RU (1) RU2015137298A (zh)
WO (1) WO2014135473A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180305348A1 (en) * 2015-06-02 2018-10-25 Pharmacyclics Llc Inhibitors of brutons tyrosine kinase
US10562902B2 (en) 2015-08-13 2020-02-18 Beijing Hanmi Pharmaceutical Co., Ltd. IRAK4 inhibitor and use thereof
AU2016369584A1 (en) 2015-12-16 2018-07-19 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
WO2017205762A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US10961247B2 (en) * 2016-06-30 2021-03-30 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
US11542233B2 (en) * 2016-12-23 2023-01-03 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
WO2018139883A1 (ko) * 2017-01-26 2018-08-02 부광약품 주식회사 다중 표적 키나아제 저해제로서 융합피리미딘 유도체
RU2758370C1 (ru) * 2017-12-28 2021-10-28 Даевунг Фармасьютикал Ко., Лтд. Производные оксифторпиперидина в качестве ингибитора киназы
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2550000A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Neue purin-derivate und verfahren zu ihrer herstellung
JPS606616A (ja) * 1983-06-24 1985-01-14 Ishihara Sangyo Kaisha Ltd 血管拡張剤
ZA858154B (en) * 1984-10-26 1986-06-25 Warner Lambert Co N6-substituted deoxyribose analogs of adenosines
JPS61256346A (ja) * 1985-05-10 1986-11-13 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
JPH0642039B2 (ja) * 1985-09-05 1994-06-01 コニカ株式会社 直接ポジ画像の形成方法
IL86007A0 (en) * 1987-04-09 1988-09-30 Wellcome Found 6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them
JPH0196644A (ja) * 1987-10-07 1989-04-14 Konica Corp 直接ポジ型ハロゲン化銀写真感光材料
PT95516A (pt) * 1989-10-06 1991-08-14 Wellcome Found Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
NZ579248A (en) * 2007-03-28 2011-08-26 Neurosearch As Purinyl derivatives and their use as potassium channel modulators
EP2219646A4 (en) * 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
WO2010068806A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
WO2010111406A2 (en) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
WO2012034719A1 (en) * 2010-09-14 2012-03-22 Centre National De La Recherche Scientifique Novel antiviral acyclic nucleoside phosphonates
EP2632898A4 (en) * 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
SG10201604682VA (en) * 2011-06-10 2016-07-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity

Also Published As

Publication number Publication date
WO2014135473A1 (en) 2014-09-12
US9469644B2 (en) 2016-10-18
CN105073750A (zh) 2015-11-18
US20160002243A1 (en) 2016-01-07
KR20150113195A (ko) 2015-10-07
MX2015010466A (es) 2015-10-30
EP2964647A1 (en) 2016-01-13
RU2015137298A (ru) 2017-04-10
CA2902375A1 (en) 2014-09-12
BR112015021677A2 (pt) 2017-07-18
JP2016513621A (ja) 2016-05-16

Similar Documents

Publication Publication Date Title
IL279258B (en) tyrosine kinase inhibitors
HK1224173A1 (zh) 布魯頓氏酪氨酸激酶抑制劑和 抑制劑的組合
HK1212689A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1211293A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
ZA201603337B (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
HK1220459A1 (zh) 激酶抑制劑
HK1194381A1 (zh) 酪氨酸激酶抑制劑
HK1219421A1 (zh) 激酶抑制劑的組合及其用途
HK1210779A1 (zh) 酪氨酸激酶抑制劑
SG11201600062RA (en) Pyrimidine derivatives as kinase inhibitors
HK1197060A1 (zh) 酪氨酸激酶抑制劑
HK1210461A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1211578A1 (zh) 作為 激酶抑制劑的酰氨基咪唑並噠嗪
HK1217695A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1219104A1 (zh) 激酶抑制劑
EP2988744A4 (en) THIAZOLE SUBSTITUTED AMINOHETEROARYL COMPOUNDS TYLOSINE KINASE SPLENIC INHIBITORS
HK1218416A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1200816A1 (zh) 布魯頓酪氨酸激酶抑制劑
IL243295A0 (en) Carbazole carboxamide compounds are useful as kinase inhibitors
EP2968358A4 (en) NOVEL CHOLINKINASE INHIBITORS
HK1215855A1 (zh) 酪氨酸蛋白激酶抑制劑
EP2968995A4 (en) INHIBITORS OF LRRK2 KINASE ACTIVITY
HK1212975A1 (zh) 作為布魯頓氏酪氨酸激酶抑制劑的噻唑衍生物
EP2968331A4 (en) PYRROLOPYRIMIDINE COMPOUNDS AS KINASEINHIBITORS
HK1218394A1 (zh) 酪氨酸蛋白激酶抑制劑